dc.contributor.author | Aktas, Gülseren | |
dc.date.accessioned | 2021-03-02T23:20:30Z | |
dc.date.available | 2021-03-02T23:20:30Z | |
dc.date.issued | 2017 | |
dc.identifier.citation | Aktas G., "In-vitro activity of ceftriaxone combined with newer agents against MRSA", JOURNAL OF CHEMOTHERAPY, cilt.29, sa.6, ss.383-385, 2017 | |
dc.identifier.issn | 1120-009X | |
dc.identifier.other | av_11dc5c06-ee37-446e-80a7-45b64fcfa1fc | |
dc.identifier.other | vv_1032021 | |
dc.identifier.uri | http://hdl.handle.net/20.500.12627/17471 | |
dc.identifier.uri | https://doi.org/10.1080/1120009x.2016.1246633 | |
dc.description.abstract | In this study, in vitro synergism in combinations of agents as ceftriaxone/dalbavancin, ceftriaxone/linezolid and ceftriaxone/daptomycin against MRSA strains were investigated. Thirty clinical MRSA strains were tested. The minimum inhibitory concentrations of all antibiotics were determined using reference broth microdilution method. In-vitro activities of antibiotics combined against the strains were tested using two-dimensional checkerboard microdilution method. Results were interpreted as follows: synergy = FICI 0.5-4. The MIC50, MIC90 and MICrange of ceftriaxone, daptomycin, dalbavancin and linezolid were found as 128, 1024 and 16-2048 mg/L; 1, 1 and 0.5-1 mg/L; 0.12, 0.12 and 0.03-0.12 mg/L; and 1, 2 and 1-2 mg/L, respectively. Our results showed that the frequency of synergistic effects (FICI: 4) was observed. | |
dc.language.iso | eng | |
dc.subject | Dahili Tıp Bilimleri | |
dc.subject | Farmakoloji ve Toksikoloji | |
dc.subject | Tıp | |
dc.subject | Sağlık Bilimleri | |
dc.subject | Temel Tıp Bilimleri | |
dc.subject | Biyokimya | |
dc.subject | İç Hastalıkları | |
dc.subject | Onkoloji | |
dc.subject | Cerrahi Tıp Bilimleri | |
dc.subject | Patoloji | |
dc.subject | Eczacılık | |
dc.subject | Temel Eczacılık Bilimleri | |
dc.subject | Yaşam Bilimleri | |
dc.subject | Temel Bilimler | |
dc.subject | ONKOLOJİ | |
dc.subject | Klinik Tıp | |
dc.subject | Klinik Tıp (MED) | |
dc.subject | BULAŞICI HASTALIKLAR | |
dc.subject | İmmünoloji | |
dc.subject | Yaşam Bilimleri (LIFE) | |
dc.subject | PATOLOJİ | |
dc.subject | Biyoloji ve Biyokimya | |
dc.subject | FARMAKOLOJİ VE ECZACILIK | |
dc.title | In-vitro activity of ceftriaxone combined with newer agents against MRSA | |
dc.type | Makale | |
dc.relation.journal | JOURNAL OF CHEMOTHERAPY | |
dc.contributor.department | İstanbul Üniversitesi , İstanbul Üniversitesi, İstanbul Tıp Fakültesi, , Temel Tıp Bilimleri | |
dc.identifier.volume | 29 | |
dc.identifier.issue | 6 | |
dc.identifier.startpage | 383 | |
dc.identifier.endpage | 385 | |
dc.contributor.firstauthorID | 97050 | |